Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
Biodexa has recruited 87 subjects, exceeding 50% of its target of 168, for the registrational Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis. The trial is currently active at 29 clinical sites across the US and Europe, with a futility analysis planned after 25 Progression Free Survival events.
Key figures
- Drug Name
- eRapa
- Phase Of Trial
- Phase 3
- Trial id
- NCT06950385
- Grant amount
- $20 million
- Subjects target
- 168
- Subjects recruited
- 87
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.